ClinicalTrials.gg
Status unknownNCT01557816Updated Mar 22, 2012

Trial of Naproxen to Evaluate Various Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee

An interventional study of Naproxen and Placebo in Osteoarthritis, Knee, sponsored by Analgesic Solutions. Status unknown at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2012-03-22.

Sponsored by Analgesic Solutions · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2012), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 152 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Planned enrollment
348th of 691
70 · median 72
Started
2011
with 24 others
No phase
376 of 796
54 open now
Registered
165th of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 348th largest by planned enrollment of the 691 interventional ones that give a count, is one of 25 that started in 2011, is one of 376 with no phase, and was the 165th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

This study aims to evaluate various methods of measuring pain relief in subjects who have chronic OA of the knee. After a 1 week of wash-out from existing therapy, subjects will be treated in a blinded fashion for 1 week with either naproxen (3 days at 250 mg twice a day followed by 4 days at 500 mg twice a day) or placebo. After the first week of treatment, subjects will have another week of wash-out followed by a second period of 1 week of the alternate treatment. Subjects will not be allowed to use oral non-steroidal anti-inflammatory drugs (NSAIDs) or other oral analgesics, or topical medications on their target knees during the study. Acetaminophen will be allowed as a rescue medication.

Read the detailed description

This study aims to evaluate various methods of measuring pain relief in osteoarthritis (OA) of the knee. The duration of the study will be up to 5 weeks. Eligible subjects will have chronic OA of the knee. After meeting initial entry criteria and prior to randomization, there will be a 1 week wash-out from existing therapy. Subjects will then be treated in a blinded fashion for 1 week with either naproxen (3 days at 250 mg twice a day followed by 4 days at 500 mg twice a day) or placebo. After the first week of treatment, subjects will have a week of wash-out followed by a second period of 1 week of the alternate treatment. Subjects will not be allowed to use oral non-steroidal anti-inflammatory drugs (NSAIDs) or other oral analgesics, nor will they be allowed to use topical medications on their target knees during the study. Acetaminophen will be allowed as a rescue medication (as needed up to 2 g/day)but subjects will be told not to take acetaminophen at least 12 hours before study visits. Seventy (70) subjects will be randomized to ensure that 60 subjects complete both treatment arms.

03

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • osteoarthritis
  • knee
  • Naproxen
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject able to read, comprehend and sign written Form
  2. Subject is 21 years old or older
  3. If female, should be or has negative urine test
  4. Subject has some degree of target joint pain for the last 3 months
  5. Subject has to have 3 out of six:

    ( )Age > 50 ( )Morning stiffness \< 30 minutes ( )Crepitus on active motion ( )Bony enlargement ( )No palpable warmth of synovium

  6. Subject had an X-ray of the target knee showing evidence of OA within the past 3 years
  7. Target joint does not contain any type of orthopedic and/or prosthetic device
  8. Subject is ambulatory
  9. Subject is in good general medical and psychological health, and is capable of completing study assessments and procedures.

Exclusion criteria

Exclusion Criteria:

  1. Subject had an x-ray of the target knee showing Kellgren-Lawrence grade 4
  2. Subject has any pain syndrome that has the potential to confound the assessment of the target knee.
  3. the subject has a documented history of an adverse reaction to NSAIDs or acetaminophen
  4. Subject is pregnant or breast feeding
  5. Subject has sitting systolic pressure > 180 mmHg or \< 90mmHg, and/or a sitting diastolic pressure > 100 mmHg or \< 50 mmHg at screening
  6. Subject has mass body index () > 35 kg/m2.
  7. Subject has a Hospital Anxiety and Depression Scale (HADS) score > 12 on either subscale or has an established history of major depressive disorder not controlled with medication
  8. Subject has had an introduction of physiotherapy, acupuncture, or transcutaneous electrical nerve stimulation within 4 weeks before screening, or has no stable regimen of these modalities.
  9. Subject has a abnormalities in clinical chemistry, hematology, coagulation, or urinalysis.
  10. Subject has a significant history or renal impairment
  11. Subject has a positive urine drug screen for alcohol, illicit drugs or nonprescribed controlled substances
  12. Subject has dermatological lesions of the target knee or ipsilateral elbow at the time of screening.
  13. Subject is unable to discontinue all formulations of prior analgesics
  14. Subject has received any drug within 30 days prior to screening
  15. Subject has a history of active peptic ulceration, gastrointestinal bleeding, esophageal, or gastric or duodenal ulcer within 3 months of screening
  16. Subject has had a surgical intervention for any pain within 3 months of screening or plans for surgical intervention while in the study
  17. Subject has a documented history of inflammatory arthritis, including rheumatoid arthritis.
  18. Subject has received local injections, viscosupplementation, or arthrocentesis in the target joint within 3 months of screening
  19. Subject has received oral or intramuscular corticosteroids within the past 30 days
  20. Subject is involved in an ongoing or settled worker's compensation claim, disability, or litigation related to any pain problem
  21. Subject had used opioids for pain more than 4 days in the week preceding screening
  22. Subject has a history of alcohol or drug abuse/dependence/misuse within 2 years of screening
  23. Subject has history of acute coronary syndrome, ischemic or hemorrhagic stroke, , or previous revascularization procedure to coronary or peripheral vasculature, or has a history of congestive heart failure within 5 years of screening
  24. Subject has had axillary lymph nodes removed bilaterally
  25. Subject has a disease-related or iatrogenic coagulopathy, or had been diagnosed with thrombocytopenia or a functional disorder
  26. The subject is currently on an aromatase inhibitor.
  27. Subject has a history of any condition that, in the Investigator's opinion, precludes participation in the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Naproxen

    Drug: Naproxen · Drug: Placebo

  • Sham comparator
    Placebo

    Drug: Naproxen · Drug: Placebo

Interventions

  • Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.

    Also known as: Aleve, Naprosyn

  • DrugPlacebo

    Placebo for seven days given BID during either of the 2 treatment periods.

    Also known as: Sugar pill

06

What researchers measure

Primary outcomes

  1. Efficacy of naproxen vs. placebo

    Efficacy of naproxen VS placebo will be analyzed by efficacy end-points of within-subject difference. Efficacy evaluations will include: * In-clinic pain intensity NRS (24-hour recall) * WOMAC: pain subscale, stiffness subscale, function subscale, and total scores * Daily actiwatch pain intensity * In-clinic pain intensity NRS for curent pain at rest and after exercise * Thermal pain matching at rest and after exercise * PGIC (Patient's Global Impression of Change) * Subject treatment reference

    Time frame: 5 weeks

  2. Safety

    Safety of Naproxen VS Placebo Safety evaluations will include: * Adverse events (AEs)and serious AEs (SAEs) * Vital signs * Clinical Laboratories * Concomitant medications

    Time frame: 5 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2012
First posted
Mar 20, 2012
Start
Dec 2011
Primary completionEst.
Jun 2012
CompletionEst.
Jun 2012
Last update
Mar 22, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01557816
Lead sponsor
Analgesic Solutions
Responsible party
Sponsor
First posted
Mar 20, 2012
Start date
Dec 2011
Primary completion
Jun 2012 (estimated)
Completion
Jun 2012 (estimated)
Last update
Mar 22, 2012

Study contacts

Stephen Wright, M.D.
Contact
swright@analgesicsolutions.com
781-444-9605 ext. 101
Pura Requintina, Ph.D.
Contact
prequintina@analgesicsolutions.com
781-444-9605 ext. 121
Stephen Wright, MD
principal investigator · Analgesic Solutions

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naproxen

Start the discussion